Umbrella Study for Analysis of Data Related to Patients With Cancer
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Tempus AI
- 入组人数
- 77
- 试验地点
- 19
- 主要终点
- Provide RWD/E Datasets to Research Collaborators to Support Commercialization
研究概览
简要总结
This study is a multisite, minimal risk, non-interventional study using patient electronic health record data collected as part of standard of care to answer cohort-based research questions and create robust real-world data sets.
详细描述
One key purpose of the Study is to collect data that may be used for a wide range of scientific questions and real-world insights.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must be diagnosed with cancer
- •Medical records available to meet cohort requirements
排除标准
- 未提供
研究组 & 干预措施
Patients with cancer
No intervention or sample collection is required on the study.
结局指标
主要结局
Provide RWD/E Datasets to Research Collaborators to Support Commercialization
时间窗: 5 years
Use data analysis to enable more precise characterization of biomarker testing rates, factors influencing access to testing, and uptake of recently approved therapies to inform commercial strategy for pharmaceutical companies and generate evidence for payors.
Provide RWD/E Datasets to Research Collaborators to Support Development
时间窗: 5 years
Use data analysis to enable deeper understanding of patient population characteristics and outcomes to more accurately assess clinical trial feasibility and optimize trial design.
Provide RWD/E Datasets to Research Collaborators to Support Real-World Insights
时间窗: 5 years
Use data analysis to further understanding of variations in patient care across the US to help ensure patients have access to optimal testing and treatment.
Provide RWD/E Datasets to Research Collaborators to Support Regulatory
时间窗: 5 years
Use data analysis to generate supplemental data for new accelerated approval pathway filings and provide real world control arms where necessary.
Provide RWD/E Datasets to Research Collaborators to Support Phase IV Surveillance
时间窗: 5 years
Use data analysis to support post approval understanding of longer term side effects that may not be sufficiently detected via randomized clinical trials.
次要结局
未报告次要终点